Antitumor Activity and Toxicity of Olivamide Dosage Form, a New Semi-Synthetic Olivomycin a Derivative
- Authors: Treshchalin I.D.1, Treshchalin M.I.1, Tevyashova A.N.1,2, Pereverzeva E.R.1
-
Affiliations:
- G. F. Gause Institute of New Antibiotics
- D. Mendeleev University of Chemical Technology of Russia
- Issue: Vol 52, No 11 (2019)
- Pages: 902-906
- Section: Article
- URL: https://journals.rcsi.science/0091-150X/article/view/245529
- DOI: https://doi.org/10.1007/s11094-019-01923-2
- ID: 245529
Cite item
Abstract
Methods for selective chemical modification of the antibiotic olivomycin A (OA) were developed at G. F. Gause Institute of New Antibiotics. The compound with the highest activity against various tumor cell lines was selected from a series of OA analogs. The aim of the work was to study the antitumor activity and toxicity of a dosage form of this compound, i.e., olivamide. Antitumor activity was studied in four syngenic grafted murine tumors. Chronic toxicity was assessed in experiments with rats that determined the animal body mass, clinical and biochemical blood analysis, urinalysis, electrocardiography, and structures of internal organs. The preparation exhibited high antitumor activity and displayed dose-dependent nephro- and hepatotoxic properties.
Keywords
About the authors
I. D. Treshchalin
G. F. Gause Institute of New Antibiotics
Email: chulis@mail.ru
Russian Federation, 11/1 Ul. Bol?shaya Pirogovskaya, Moscow, 119021
M. I. Treshchalin
G. F. Gause Institute of New Antibiotics
Email: chulis@mail.ru
Russian Federation, 11/1 Ul. Bol?shaya Pirogovskaya, Moscow, 119021
A. N. Tevyashova
G. F. Gause Institute of New Antibiotics; D. Mendeleev University of Chemical Technology of Russia
Author for correspondence.
Email: chulis@mail.ru
Russian Federation, 11/1 Ul. Bol?shaya Pirogovskaya, Moscow, 119021; 9 Miusskaya Sq, Moscow, 125047
E. R. Pereverzeva
G. F. Gause Institute of New Antibiotics
Email: chulis@mail.ru
Russian Federation, 11/1 Ul. Bol?shaya Pirogovskaya, Moscow, 119021